CF
RVNC

CNA Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

CNA Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,510
Closed -$516K – 203
2021
Q3 		$516K Buy
18,510
+1,410
+8% +$40.2K 0.14% 159
2021
Q2 		$507K Sell
17,100
-2,700
-14% -$77.9K 0.14% 159
2021
Q1 		$553K Buy
19,800
+1,710
+9% +$47.3K 0.17% 154
2020
Q4 		$513K Buy
18,090
+3,900
+27% +$101K 0.16% 155
2020
Q3 		$357K Sell
14,190
-1,450
-9% -$38K 0.13% 160
2020
Q2 		$382K Buy
+15,640
New +$309K 0.15% 153

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

CNA Financial's RVNC Position: Q4 2021 in Review

CNA Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 18,510 shares — an estimated $516K sold.

CNA Financial first reported a position in RVNC in Q2 2020 and held it in 6 quarters. The position peaked at $553K in Q1 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • CNA Financial reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • CNA Financial sold 18,510 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $516K.
  • CNA Financial first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
  • CNA Financial's Revance Therapeutics, Inc. position peaked at $553K in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on CNA Financial's 13F filing for Q4 2021, filed 11 Feb 2022.